Androgen receptor splice variants (AR-Vs) - which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples - lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.
ASJC Scopus subject areas